The association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients

Journal of Vascular Surgery

Volumn 46, Issue 3, 2007, Pages 500-506

  Allison, Matthew A ^a   Denenberg, Julie O ^a   Nelson, Jeanenne J ^b   Natarajan, Loki ^a   Criqui, Michael H ^a  

^a Department of Family and Preventive Medicine ^*

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPASE A2; TRIACYLGLYCEROL;

AGED; ARTERY DISEASE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUCASIAN; CLINICAL EXAMINATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; INTERVIEW; ISCHEMIC HEART DISEASE; LEG ARTERY; MAJOR CLINICAL STUDY; MALE; MASS; MEDICAL RECORD REVIEW; MORTALITY; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX RATIO; SURVIVOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BIOLOGICAL MARKERS; CALIFORNIA; CARDIOVASCULAR DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PLETHYSMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER;

EID: 34548459282     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2007.04.038     Document Type: Article

References (31)

1. Tjoelker L.W., Wilder C., Eberhardt C., Stafforini D.M., Dietsch G., Schimpf B., et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374 (1995) 549-553
2. Zalewski A., and Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25 (2005) 923-931
3. Stafforini D.M., McIntyre T.M., Carter M.E., and Prescott S.M. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 262 (1987) 4215-4222
4. Tselepis A.D., Dentan C., Karabina S.A., Chapman M.J., and Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 15 (1995) 1764-1773
5. Hakkinen T., Luoma J.S., Hiltunen M.O., Macphee C.H., Milliner K.J., Patel L., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 19 (1999) 2909-2917
6. Virmani R., Kolodgie F.D., Burke A.P., Farb A., and Schwartz S.M. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20 (2000) 1262-1275
7. Kolodgie F.D., Burke A.P., Skorija K.S., Ladich E., Kutys R., Makuria A.T., et al. Lipoprotein-associated phospholipase a2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2523-2529
8. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
9. Macphee C.H., Nelson J.J., and Zalewski A. Lipoprotein-associated phospholipase A2 as a target of therapy. Curr Opin Lipidol 16 (2005) 442-446
10. Packard C.J., O'Reilly D.S., Caslake M.J., McMahon A.D., Ford I., Cooney J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
11. Blake G.J., Dada N., Fox J.C., Manson J.E., and Ridker P.M. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38 (2001) 1302-1306
12. Ballantyne C.M., Hoogeveen R.C., Bang H., Coresh J., Folsom A.R., Heiss G., and Sharrett A.R. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
13. Koenig W., Khuseyinova N., Lowel H., Trischler G., and Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
14. Oei H.H., van der Meer I.M., Hofman A., Koudstaal P.J., Stijnen T., Breteler M.M., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111 (2005) 570-575
15. Brilakis E.S., McConnell J.P., Lennon R.J., Elesber A.A., Meyer J.G., and Berger P.B. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26 (2005) 137-144
16. Thulesius O. Principles of pressure measurement. In: Bernstein E. (Ed). Non-invasive diagnostic techniques in vascular disease (1985), CV Mosby, St. Louis, Mo 77-82
17. Fowkes F.G., Housley E., Macintyre C.C., Prescott R.J., and Ruckley C.V. Variability of ankle and brachial systolic pressures in the measurement of atherosclerotic peripheral arterial disease. J Epidemiol Community Health 42 (1988) 128-133
18. Osmundson P.J., O'Fallon W.M., Clements I.P., Kazmier F.J., Zimmerman B.R., and Palumbo P.J. Reproducibility of noninvasive tests of peripheral occlusive arterial disease. J Vasc Surg 2 (1985) 678-683
19. Johnston K.W., Hosang M.Y., and Andrews D.F. Reproducibility of noninvasive vascular laboratory measurements of the peripheral circulation. J Vasc Surg 6 (1987) 147-151
20. Caslake M.J., Packard C.J., Suckling K.E., Holmes S.D., Chamberlain P., and Macphee C.H. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
21. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 340 (1999) 115-126
22. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 91 (2003) 3A-6A
23. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull Jr. W., et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb Vasc Biol 15 (1995) 1512-1531
24. Stary H.C., Chandler A.B., Glagov S., Guyton J.R., Insull Jr. W., Rosenfeld M.E., et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89 (1994) 2462-2478
25. Macphee C., Benson G.M., Shi Y., and Zalewski A. Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opin Investig Drugs 14 (2005) 671-679
26. Zalewski A., Macphee C., and Nelson J.J. Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 527-532
27. O'Donoghue M., Morrow D.A., Sabatine M.S., Murphy S.A., McCabe C.H., Cannon C.P., and Braunwald E. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) Trial. Circulation 113 (2006) 1745-1752
28. Corsetti J.P., Rainwater D.L., Moss A.J., Zareba W., and Sparks C.E. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 52 (2006) 1331-1338
29. Yang E.H., McConnell J.P., Lennon R.J., Barsness G.W., Pumper G., Hartman S.J., et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 26 (2006) 106-111
30. Iribarren C., Gross M.D., Darbinian J.A., Jacobs Jr. D.R., Sidney S., and Loria C.M. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: The CARDIA Study. Arterioscler Thromb Vasc Biol 25 (2005) 216-221
31. Kardys I., Oei H.-H.S., van der Meer I.M., Hofman A., Breteler M.M.B., and Witteman J.C.M. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam study. Arterioscler Thromb Vasc Biol 26 (2006) 631-636